News

The latest press releases, publications, and events for Innoviva Specialty Therapeutics

Filter by:

All News Press Releases Events

12.12.2025

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Read More

06.11.2025

In-vitro Activities of Zoliflodacin and Solithromycin Against Neisseria gonorrhoeae Isolates from Korea

Read More

05.05.2025

High susceptibility to the novel antimicrobial zoliflodacin among Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024

Read More

01.22.2025

Zoliflodacin: Addressing a growing global threat through a novel public-private development partnership

Read More

01.22.2025

Oral zoliflodacin is non-inferior to a combination of ceftriaxone and azithromycin for treatment of uncomplicated urogenital gonorrhoea: Results of a large global Phase 3 randomised controlled trial

Read More

01.22.2025

Oral zoliflodacin for treatment of uncomplicated gonorrhea Subgroup analyses by sex at birth, race and region of a global Phase 3 randomized controlled clinical trial

Read More

01.22.2025

Recommendations for the optimal introduction of novel antibiotics to treat uncomplicated gonorrhoea in the face of increasing antimicrobial resistance: a case study with zoliflodacin

Read More

01.22.2025

Descriptive analysis of sexually transmitted infections risk factors among participants included in the global zoliflodacin Phase 3 clinical trial

Read More

01.22.2025

In Vitro Activity of Zoliflodacin against Contemporary Neisseria gonorrhoeae isolate from the United States

Read More

12.11.2024

Oral zoliflodacin is non-inferior to a combination of ceftriaxone and azithromycin for treatment of uncomplicated urogenital gonorrhoea: results of a large global Phase 3 randomised controlled trial

Read More